PRESS RELEASE

NERVIANO MEDICAL SCIENCES

Nerviano Medical Sciences announces participation at AACR 2026 with two poster presentations

Milan, Italy, 16 April 2026 – Nerviano Medical Sciences S.r.l. ("NMS"), a global oncology-focused biopharmaceutical company, is proud to announce its participation in the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place in San Diego, USA from April 17 to 22, 2026. At the meeting, NMS will present two scientific posters highlighting its latest research and advancements in oncology. In addition, research from NMS scientists will be featured in a poster to be presented by Italfarmaco S.p.A., a private pharmaceutical company with a strong research focus.

At this year's AACR Annual meeting, NMS will present the following posters:

-NMS Poster 1
Title: "Atamparib: first-in-class PARP7 inhibitor for treatment of NSCLC adenocarcinoma in monotherapy and in combination with standards of care" (Poster #3049)
Presenter: Genny Degani, Biology Lead Scientist at NMS
Location: Poster Section 15; Poster Board Number: 10
Date & Time: April 20, 2026, 2:00 PM – 5:00 PM PDT
This study presents a novel mechanism of action linking PARP7 to MAP-kinase pathway through the oncogene FRA1, which supports atamparib activity in MAPK-dependent cancers, demonstrated by *in vitro* and *in vivo* data generated in monotherapy or in combination with multiple KRAS inhibitors.
Link to full poster abstract https://www.abstractsonline.com/pp8/#!/21436/presentation/8884

-NMS Poster 2
Title: "Itareparib: a potent, selective and non-trapper PARP1 inhibitor for combination therapy with DNA damaging agents in solid tumors" (Poster #2933)
Presenter: Alessia Montagnoli, CSO at NMS
Location: Poster Section 11; Poster Board Number: 10
Date & Time: April 20, 2026, 2:00 PM - 5:00 PM PDT
Itareparib is a third-generation PARP1 selective inhibitor with a unique non-trapping mechanism designed to expand the application of PARP1i through chemotherapy or ADC combinations, addressing the unmet need of patients with both HR-deficient and HR-proficient tumors. In this presentation we will show itareparib is highly synergic with chemotherapy agents such as temozolomide, topoisomerase I inhibitors and with Topo1-ADC in multiple tumor types with low hematological effects compared to trapper PARP1 inhibitors, irrespectively from PARP1 selectivity. These data strongly support the ongoing Phase I/II clinical trials of itareparib in combination with DNA-damaging agents in brain (NCT04910022), lung (NCT06931626) and ovarian cancer (NCT06930755)
Link to full poster abstract https://www.abstractsonline.com/pp8/#!/21436/presentation/3439

-Italfarmaco (ITF) - Poster featuring NMS out-licensed duocarmycin payload

PRESS RELEASE

NERVIANO MEDICAL SCIENCES

Title: “Targeted DNA damage through SSTR2: Preclinical development of a novel peptide-drug conjugate for neuroendocrine tumors” (Poster #1758)
Presenter: Gianluca Fossati, Head of Biochemistry at Italfarmaco
Location: Poster Section 15; Poster Board Number: 1758
Date & Time: April 20, 2026, 9:00 AM -12:00 PM PDT
NMS and ITF announce the presentation of new preclinical data for ITF3912, a novel peptide-drug conjugate (PDC) developed under their licensing agreement, leveraging NMS’s proprietary linker-payload technology. ITF3912 targets somatostatin receptor 2 (SSTR2), which is expressed in neuroendocrine tumors and a subset of small cell lung cancers, and combines a modified octreotide analog with NMS’s duocarmycin payload via a cathepsin-B cleavable linker.
As detailed in the abstract, ITF3912 demonstrates high affinity and selectivity for SSTR2, efficient receptor-mediated internalization, and targeted intracellular release of its payload, resulting in DNA damage and tumor cell death. Antitumor activity, observed in vitro and in vivo, and correlated with SSTR2 expression levels, including in SCLC xenograft models. These findings support the continued development of ITF3912 as a potential therapeutic option for patients with SSTR2-positive tumors. The compound is currently advancing through IND-enabling studies.
Link to full poster abstract https://www.abstractsonline.com/pp8/#!/21436/presentation/4315

We look forward to engaging with the scientific community at AACR 2026 and sharing insights from our work.

About NMS

NMS is a global, integrated biopharmaceutical company focused on the discovery and development of innovative oncology therapies. With affiliates in Nerviano/Corsico (Italy), Boston (USA), and Shanghai (China), NMS leverages deep expertise in drug discovery and translational medicine to advance its pipeline of novel candidates from bench to bedside.

For more information, visit https://www.nervianoms.com

Media Relations: mediarelations@nervianoms.com